Located in the Winter Street office park in Waltham, EdiGene’s 14,000 sq. ft. space holds laboratories integrated with office space.
LEAPER (Leveraging endogenous ADAR for programmable editing of RNA) was developed in a lab at Peking University led by Professor Wensheng Wei, the Scientific Founder of EdiGene, and was first reported in Nature Biotechnology in 2019. In February 2022, Professor Wei’s lab published a research article in Nature Biotechnology on an upgraded version of LEAPER that shows significantly improved efficiency and fidelity of RNA editing in vitro and in vivo.
“Moving into our new R&D Center is a significant milestone for EdiGene. It marks our continued efforts to advance the development of and accelerate the translation of our exciting RNA editing technology at the global level," said Dong Wei, Ph.D., CEO of EdiGene. “With a strong foundation in RNA editing and translational expertise, we are committed to developing genetic medicines to address the unmet medical needs for patients around the world."
“We have been building on our R&D efforts in the greater Boston area with a growing team responsible for drug discovery and development, AAV process development, bioinformatics and clinical development for almost two years,” said Bo Zhang, Ph.D., Head of EdiGene’s U.S. subsidiary EdiGene Biotechnology USA.
“We are excited to move into our new site to accommodate our rapidly expanding workforce and laboratory operations. By leveraging our unique platform, our team of talented scientists and professionals are creating innovative therapies through internal R&D efforts and external partnerships.”
A recent opening ceremony for the new site hosted representatives from patient advocacy groups, academic and research institutions, industry peers and partners, and investors.
Founded in 2015, EdiGene is headquartered in Beijing, with offices in Guangzhou and Shanghai, China, and Waltham, Massachusetts site in the US.